CN102256952B - 用作葡萄糖激酶激活剂的芳基环丙基乙酰胺衍生物 - Google Patents

用作葡萄糖激酶激活剂的芳基环丙基乙酰胺衍生物 Download PDF

Info

Publication number
CN102256952B
CN102256952B CN200980150686XA CN200980150686A CN102256952B CN 102256952 B CN102256952 B CN 102256952B CN 200980150686X A CN200980150686X A CN 200980150686XA CN 200980150686 A CN200980150686 A CN 200980150686A CN 102256952 B CN102256952 B CN 102256952B
Authority
CN
China
Prior art keywords
compound
acceptable salt
glucose
pharmaceutically acceptable
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980150686XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102256952A (zh
Inventor
A·B·布埃诺梅伦多
F·J·阿赫哈斯-奇卡罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102256952A publication Critical patent/CN102256952A/zh
Application granted granted Critical
Publication of CN102256952B publication Critical patent/CN102256952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980150686XA 2008-12-19 2009-12-11 用作葡萄糖激酶激活剂的芳基环丙基乙酰胺衍生物 Active CN102256952B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380341.1 2008-12-19
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
US61/153,781 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (2)

Publication Number Publication Date
CN102256952A CN102256952A (zh) 2011-11-23
CN102256952B true CN102256952B (zh) 2013-12-11

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150686XA Active CN102256952B (zh) 2008-12-19 2009-12-11 用作葡萄糖激酶激活剂的芳基环丙基乙酰胺衍生物

Country Status (34)

Country Link
US (1) US8063079B2 (https=)
EP (1) EP2379517B1 (https=)
JP (1) JP5497064B2 (https=)
KR (1) KR101290437B1 (https=)
CN (1) CN102256952B (https=)
AR (1) AR074470A1 (https=)
AU (1) AU2009335931B2 (https=)
BR (1) BRPI0923183B1 (https=)
CA (1) CA2746746C (https=)
CO (1) CO6382120A2 (https=)
CR (1) CR20110342A (https=)
DK (1) DK2379517T3 (https=)
DO (1) DOP2011000197A (https=)
EA (1) EA019055B1 (https=)
EC (1) ECSP11011150A (https=)
ES (1) ES2435242T3 (https=)
HR (1) HRP20130983T1 (https=)
IL (1) IL213210A (https=)
JO (1) JO2979B1 (https=)
MA (1) MA32902B1 (https=)
MX (1) MX2011006434A (https=)
MY (1) MY180567A (https=)
NZ (1) NZ592930A (https=)
PA (1) PA8851901A1 (https=)
PE (1) PE20120339A1 (https=)
PL (1) PL2379517T3 (https=)
PT (1) PT2379517E (https=)
SG (1) SG172256A1 (https=)
SI (1) SI2379517T1 (https=)
TN (1) TN2011000294A1 (https=)
TW (1) TWI395748B (https=)
UA (1) UA104742C2 (https=)
WO (1) WO2010080333A1 (https=)
ZA (1) ZA201103944B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2006058923A1 (en) * 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2007051847A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010745A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR100890695B1 (ko) 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
RU2008103142A (ru) * 2005-07-01 2009-08-10 Новартис АГ (CH) Комбинация органических соединений
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
KR20090025358A (ko) * 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 글루코키나제 활성화제로서의 피라졸
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2006058923A1 (en) * 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2007051847A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators

Also Published As

Publication number Publication date
JO2979B1 (en) 2016-03-15
BRPI0923183B1 (pt) 2019-03-19
CA2746746C (en) 2013-09-24
IL213210A (en) 2015-03-31
BRPI0923183A2 (pt) 2016-02-16
AR074470A1 (es) 2011-01-19
ZA201103944B (en) 2012-11-28
AU2009335931B2 (en) 2012-05-31
JP5497064B2 (ja) 2014-05-21
WO2010080333A1 (en) 2010-07-15
DOP2011000197A (es) 2011-09-15
JP2012512874A (ja) 2012-06-07
ES2435242T3 (es) 2013-12-17
BRPI0923183A8 (pt) 2017-09-12
IL213210A0 (en) 2011-07-31
TN2011000294A1 (en) 2012-12-17
US8063079B2 (en) 2011-11-22
EP2379517B1 (en) 2013-08-28
PA8851901A1 (es) 2010-07-27
TWI395748B (zh) 2013-05-11
PL2379517T3 (pl) 2014-01-31
MA32902B1 (fr) 2011-12-01
CN102256952A (zh) 2011-11-23
SI2379517T1 (sl) 2013-10-30
SG172256A1 (en) 2011-07-28
TW201029999A (en) 2010-08-16
KR101290437B1 (ko) 2013-07-29
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
CO6382120A2 (es) 2012-02-15
KR20110086751A (ko) 2011-07-29
HRP20130983T1 (hr) 2013-11-22
PT2379517E (pt) 2013-11-21
MY180567A (en) 2020-12-02
EA019055B1 (ru) 2013-12-30
EA201170845A1 (ru) 2011-12-30
US20100160395A1 (en) 2010-06-24
AU2009335931A1 (en) 2011-07-07
CA2746746A1 (en) 2010-07-15
ECSP11011150A (es) 2011-07-29
PE20120339A1 (es) 2012-04-16
EP2379517A1 (en) 2011-10-26
UA104742C2 (uk) 2014-03-11
CR20110342A (es) 2011-09-14
MX2011006434A (es) 2011-07-19

Similar Documents

Publication Publication Date Title
EP3130583B1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2014230569B2 (en) Pyrazole-amide compound and medicinal uses therefor
RU2753607C2 (ru) Способы лечения острого повреждения почек
CN101274918A (zh) 一类取代五元杂环化合物,其制备方法和医学用途
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
WO2009051909A1 (en) Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
US20190100537A1 (en) Curcumin-boron complex and pharmaceutical containing same
US20080132519A1 (en) Heterocyclic Compounds As Pharmaceutical Agents
CN102256952B (zh) 用作葡萄糖激酶激活剂的芳基环丙基乙酰胺衍生物
CN110177774B (zh) 作为Caspase抑制剂的联环化合物
WO2008067709A1 (en) Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof
HK1159635A (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
HK1159635B (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
WO2021235508A1 (ja) 脂肪性肝疾患の治療用医薬
JP2005529160A (ja) 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物
EP3027605B1 (en) Novel indazole compounds and a process for the preparation thereof
WO2022152138A1 (zh) 稠和杂环类化合物及其制备方法和医药用途
KR20060031956A (ko) ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물
WO1992015296A1 (en) Remedy for renal diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant